Kornimate/medical-research-clean huggingface dataset:
hbsag loss/seroconversion in low replicative chronic hepatitis b virus(hbv) infection patients

Conditions: Chronic Hepatitis B

Summary: hbsag loss/seroconversion is uncommon in low replicative chronic hbv infection patients. the purpose of this study is to investigate the ability of peginterferon alpha to achieve hbsag loss/seroconversion therapy in low replicative chronic hbv infection patients with low level hbsag.

low replicative chronic hbv infection patients with low level hbsag were enrolled in the out-patient department of 3rd affiliated hospital of sun yat-sen university. all of them were hbsag positive and anti-hbs negative for more than 6 months with hbv dna\<2000 iu/ml and hbsag levels ≤1000 iu/ml. all patients did not have other liver diseases and contraindications for interferon therapy. after giving informed consent, patients were treated with weekly subcutaneous injections of alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week. the use of other immune suppressive or regulatory drugs and other antiviral drugs was prohibited during the course of the study. in this study, treatment endpoint was hbsag loss(\ 10 milli-international unit(miu)/ml) defined as seroconversion. depending on the decline of hbsag level, treatment was either continued for a prolonged period (no more than 96 weeks) until the endpoint was achieved, or terminated in case of nonresponse. treatment was proceeded if hbsag level continued to decline until hbsag seroconversion was achieved and the anti-hbs level was above 200 miu/ml. if the patients were not willing to extend treatment, the therapy was ended at the time of hbsag loss, or stopped without further decline of hbsag levels.

Eligibility criteria:
inclusion criteria: 1. hepatitis b surface antigen (hbsag) positive and \<1000 iu/ml. 2. hepatitis b surface antibody (hbsab) negative. 3. hepatitis b e antigen (hbeag) negative. 4. hepatitis b virus dna \<2000 iu/ml. 5. absence of previous antiviral therapy. exclusion criteria: 1. patients with active alcohol and/or drugs consumption. 2. patients with liver cirrhosis, hepatocellular carcinoma or other malignancies. 3. patients with other factors causing liver diseases. 4. pregnant and lactating women. 5. patients with concomitant hiv infection or congenital immune deficiency diseases. 6. patients with diabetes, autoimmune diseases. 7. patients with important organ dysfunctions. 8. patients with mental illness. 9. patients who receive antineoplastic or immunomodulatory therapy in the past 12 months. 10. patients who can't come back to clinic for follow-up on schedule.

Keywords: chronic hepatitis b peginterferon alpha
effect of three weeks consumption of rye porridge breakfast

Conditions: Obesity Prevention

Summary: acute hunger-reducing effects (8h) has been documented for rye porridge breakfast compared with iso-caloric referenced refined wheat reference breakfast. the primary aim of the current study is to investigate whether this effects remains at regular consumption. a secondary aim is to compare the orocecal transit time (octt) between the two breakfasts.

the study is randomised and cross-over. during two 3-wk periods, separated by a 3-4-wks wash out, subjects will consume test breakfasts. during one of the periods test breakfast includes rye flake porridge and during the other period test breakfast include bread made from sifted wheat. the breakfast meals will be similar in calorie-, protein-, carbohydrate- and fat content. for all other days but 1, 8 and 22 of respective test period, the breakfast foods will be handed out to the participants along with instructions to exchange their ordinary breakfast with the test foods. during day 1, 8 and 22 the breakfasts will be served at the study centre. following measurements will be made: 1. subjective ratings of hunger, satiety and desire to eat during 24 h after breakfast on day 1, 8 and 22 during each 3-wk intervention period. 2. on day 8 during each intervention period, orocecal transit time and breath hydrogen will be measured after intake of the breakfast. 3. 3 day weighed food diaries will be taken at three occasions: at baseline and during the second week of each dietary intervention period.

Eligibility criteria:
inclusion criteria: * man or woman aged between 20 and 60 years; * body mass index (bmi) 18-27 kg/m2; * habit of consuming breakfast, lunch and dinner every day; * and willingness to comply with the study procedures. exclusion criteria: * intake of medicine likely to affect appetite or food intake; * any medical condition involving the gastrointestinal tract; * eating disorder; * smoking; * consumption of more than three cups of coffee per day; * change in body weight more than 10% during three months prior to screening; * consumption of any restricted diet such as vegan, gluten-free, slimming; * pregnancy, lactation or wish to become pregnant during the study period; * any known intolerance towards salazopyrin and similar substances

Keywords: appetite whole grain
treatment of residual myopic refraction after 6 months on pseudophakic patients using relex-smile

Conditions: Pseudophakia; Myopia

Summary: the aim of this study is to assess visual and refractive outcomes after laser vision correction (lvc) - relex smile to correct residual myopic refraction after 6 months of pseudophakic (iol) implantation. before smile yag-laser capsulotomy should be performed on all patients, regardless of posterior capsule ossification, in pseudophakic patients with residual refraction. when the yag laser is applied after the smile, there will be a diopter change.

the residual myopic refraction after 6 month on pseudophakic patients using relex-smile surgery using visumax femtosecond laser.the residual myopic refractive power is between -0.75d till -5.50d.the optical zone(lenticule diameter) and cap diameter were 6.5 and 7.5 mm respectively.after dissection of both anterior and posterior planes, the lenticule was extracted through 120 degree superior 3.5mm incision and marked with a sterile marker(viscot-medster)

Eligibility criteria:
inclusion criteria: * residual myopic refraction -0.75d till -5.50d * complain visual acuity regarding residual myopic refraction exclusion criteria: * active anterior segment pathologic features * previous corneal or anterior segment surgery * glaucoma * history of ocular inflammation
analyzing ibs to identify biomarkers and microbiome signatures

Conditions: Diarrhoea Predominant Irritable Bowel Syndrome; IBS

Summary: microbiota from fecal samples from ibs-d patients, in combination with vitamin d supplementation added to our 3-d immunocompetent intestinal models will establish a high fidelity disease model to achieve our long-term goal to understand the relationship between gut microbiome, vitamin d levels, host gene expression and ibs-d symptoms that could ultimately be used as a testing platform for treatment and prevention.

the pathophysiology of ibs is not well understood. preliminary studies support ibs-d patients with varied microbiome fingerprints, vitamin d levels, and blood serotonin levels compared to non-ibs patients. the investigators have novel 3-d immunocompetent intestinal models to establish a new model of high fidelity disease to examine the relationship of ibs-d patients gut microbiome, with supplemental vitamin d levels, and the relationship of blood serotonin and vitamin d levels. ibs-d patients and healthy controls will be asked to provide a fecal sample, a biopsy sample of colonic tissue obtained during a clinically appropriate flexible sigmoidoscopy or colonoscopy, and a blood sample. there will be 1-2 office visits. one visit will last 30 minutes, the second visit no longer than 3 hours. this study is funded by a combined mayo-arizona state university seed grant. the samples will be analyzed at asu. our long-term goal is to understand the relationship between gut microbiome, vitamin d levels, host gene expression, serotonin levels, and ibs-d symptoms that could ultimately be used as a testing platform for treatment and prevention of this highly prevalent disorder.

Eligibility criteria:
inclusion criteria: ibs-d subjects: * patients who fulfill ibs-d criteria, without causes of active inflammation. * active symptoms for at least 2 months * diagnosed at least 6 months prior to enrollment healthy control: - healthy control patients should have no active infection or inflammation. exclusion criteria: * does not meet inclusion criteria * will not participate in blood draw, stool sample donation, or endoscopy * history of acute illness within 3 months of testing * any fecal transplant history

Keywords: microbiome biomarkers vitamin d serotonin
urdu version of oxford shoulder score scale: reliability and validity study

Conditions: Shoulder Pain

Summary: the primary goal of this study is to translate and culturally adapt the oxford shoulder score scale into urdu, as well as to assess its reliability and validity in the urdu-speaking pakistani community. this research will also look at the relationship between oxford shoulder score scale and the shoulder pain and disability index and short form - 36 scores for shoulder pain.

the english version of the oxford shoulder score scale will be translated and culturally modified into urdu. the oxford shoulder score scale, as well as other correlation measures, will be disseminated among 104 individuals in the pakistani urdu speaking community, who will be chosen using a convenience sample approach and based on pre-defined inclusion and exclusion criteria. for the intra- and inter-observer validity and reliability of the oxford shoulder score scale, shoulder pain and disability index, and short form - 36, questionnaires will be filled on the same day by two observers, with a two-hour gap between the first and second application. this is the inter-observer evaluation. the third application for the intra-observer evaluation will be completed after 7 days. statistical package of social sciences version 26 will be used to enter and analyses the data. the internal consistency will be assessed using the cronbach alpha value. the test-retest reliability will be assessed using an inter-class correlation coefficient. the content validity, criteria and construct validity, as well as responsiveness, of the oxford shoulder score scale scale will be assessed.

Eligibility criteria:
inclusion criteria: * age above 18 years * documented cognitive impairment * patient with shoulder instability * acute traumatic shoulder injury exclusion criteria: * age under 18 years * recent surgery * pain origination from neoplasms * systemic arthritic

Keywords: oxford shoulder score scale urdu version reliability validity shoulder pain
safety and efficacy study brimochol™ pf and carbachol pf in subjects with emmetropic phakic or pseudophakic presbyopia

Conditions: Presbyopia

Summary: safety and efficacy study of brimochol™ pf and carbachol pf in subjects with emmetropic phakic and pseudophakic presbyopia

multicenter, double-masked, randomized, safety and efficacy study of brimochol™ pf and carbachol pf topical ophthalmic solution with emmetropic phakic and pseudophakic presbyopia

Eligibility criteria:
inclusion criteria: * male or female in good general health * must have presbyopia exclusion criteria: * history of allergic reaction to the study drug or any of its components * any disease or medical condition that, in the opinion of the investigator, would prevent the subject from participating in the study or might confound study results
the effect of solvent usage on post-treatment pain

Conditions: Root Canal Infection; Pain

Summary: no clinical evidence has been yet published regarding the comparison of postoperative pain after removal of the root canal fillings with or without solvent. the aim of this study was to evaluate the effect of combined usage of protaper retreatment instruments and a gutta-percha solvent, on the postoperative pain intensity after retreatment.

scientific literature contains a few studies regarding the amount of apically extruded debris caused by solvent or solvent free use of rotary instruments. it was reported that the use of protaper retreatment instruments in combination with gutta-percha solvent reduced the amount of apically extruded debris compared to their solvent free use. nevertheless,no clinical evidence has been yet published regarding the comparison of postoperative pain after removal of the root canal fillings with or without solvent. the aim of this study was to evaluate the effect of combined usage of protaper retreatment instruments and gutta-percha solvent, on the postoperative pain intensity after retreatment. the adult patients (18-59 ages) who referred to department of endodontics with a diagnose of failed root canal treatment were examined radiographically and clinically. endodontically treated, clinically asymptomatic, single-rooted teeth with one canal exhibiting chronic periapical infection were included. a hundred cases who matched the determined criteria were selected and randomly allocated to two groups: non-solvent group (n=50): protaper retreatment instruments were used in combination with with x-smart electric motor for the removal of root canal fillings. solvent group (n=50): protaper retreatment instruments were used with the abovementioned technique but in combination with a gutta-percha solvent

Eligibility criteria:
inclusion criteria: * systemically healthy patient who has a failed root canal treatment. * asymptomatic single rooted teeth that had an initial root canal filling diagnosed with chronic apical periodontitis. * patients agreed to parcitipate in the study exclusion criteria: * overfilled teeth, * teeth with intraradicular posts, * existence of a sinus tract, * consumption of antibiotics or analgesics within one month, * pregnancy, * history of trauma, * traumatic occlusion

Keywords: postoperative pain debris extrusion filling removal solvent
efficacy and safety study of intra-articular injections of autologous peripheral blood stem cells following subchondral drilling surgery for the treatment of articular cartilage injury in the knee

Conditions: Articular Cartilage Disorder of Knee; Articular Cartilage; Degeneration

Summary: this is a 24-month, multicenter, randomized, open-label, standard treatment-controlled, parallel-group, phase 2 study for adults with large or complicated knee articular cartilage lesions and are candidates for knee joint cartilage repair surgery. the safety and efficacy of intra-articular injections of peripheral blood stem cells (pbscs) together with hyaluronic acid (ha) after subchondral drilling surgery will be evaluated to determine whether pbsc therapy can improve functional outcome and reduce pain of the knee joint better than a standard treatment (ha injections and physiotherapy regimen).

this is a 24-month, multicenter, randomized, open-label, standard treatment-controlled, parallel-group, phase 2 study for adults with large or complicated knee articular cartilage lesions and are candidates for knee joint cartilage repair surgery. the safety and efficacy of intra-articular injections of peripheral blood stem cells (pbscs) together with hyaluronic acid (ha) after subchondral drilling surgery will be evaluated to determine whether pbsc therapy can improve functional outcome and reduce pain of the knee joint better than a standard treatment (ha injections and physiotherapy regimen).

Eligibility criteria:
inclusion criteria: * aged between 18 to 55 years at screening (20 to 57 years for the open-label extension) * present for evaluation and treatment of knee pain, knee swelling, or knee mechanical symptoms due to cartilage lesions * provide written informed consent * international cartilage repair society (icrs) grade 3 or 4 lesions diagnosis from mri scans of the target knee * all subjects must also satisfy at least 1 of the following inclusion criteria: * isolated knee articular cartilage lesion (single lesion) estimated to be ≥3 cm2 as demonstrated on mri scanning. multiple knee articular cartilage lesions (multiple lesions) with at least 1 lesion estimated to be ≥3 cm2 as demonstrated on mri scanning. bipolar cartilage defects demonstrated on mri scanning with at least 1 articular surface lesion to be ≥3 cm2. one or more cartilage defects involving the patello-femoral joint as demonstrated on mri scanning with at least 1 lesion ≥3 cm2. one or more cartilage defects involving the tibio-femoral joint as demonstrated on mri scanning with at least 1 lesion to be ≥3 cm2. previously failed cartilage repair procedures (i.e., microfracture, osteochondral autograft transplantation surgery (oats), aci) exclusion criteria: * three or more previous surgical interventions on the knee in question. * preoperative flexion deformity greater than 10 degrees. * presence of ligamentous injury which would require reconstruction, varus or valgus deformity requiring osteotomy, or cases that require complex surgery prior to cartilage regeneration
disc resorption in lumbar and cervical disc herniation patients receiving integrative korean medicine treatment

Conditions: Lumbar Intervertebral Disc Displacement; Cervical Intervertebral Disc Displacement

Summary: measurement of herniated disc resorption and assessment of satisfaction regarding post-treatment state and integrative korean medicine treatment through phone interview in 500 patients with mri follow-up results receiving treatment for lumbar and cervical disc herniation at jaseng hospital of korean medicine.

intervertebral disc herniation treatment can be largely divided into conservative and surgical approaches, and the greater majority of patients show relief of symptoms and resorption of herniated disc through non-surgical, conservative management. despite concerns that early surgical interventions in intervertebral disc herniation without allowing for sufficient conservative treatment may indicate overtreatment, awareness and understanding in the general public is found somewhat lacking. the objective of this study is to measure herniated disc resorption and assess satisfaction regarding post-treatment state and integrative korean medicine treatment through phone interview in 500 patients with mri follow-up results before and after receiving conservative treatment for lumbar and cervical disc herniation at jaseng hospital of korean medicine.

Eligibility criteria:
inclusion criteria: * lumbar and/or cervical disc herniation patients with baseline mri and follow-up results after receiving treatment at jaseng hospital of korean medicine visiting between february 2012 and december 2015. * participants giving informed written consent to use of medical records for academic means. exclusion criteria: * participants refusing to participate in study or to respond to phone interview.

Keywords: magnetic resonance imaging patient satisfaction numeric rating scale
intramedullary fixation of humerus fractures without intramedullary reaming

Conditions: Humeral Fractures; Pathological Fractures

Summary: the purpose of the study is to evaluate the safety and efficacy of the composite nail - the quantum interlocking intramedullary nailing system in the reduction of humeral fractures.

the study will include 20 patients who have an acute mid shaft diaphyseal humeral fracture due to injury. the patients will undergo lateral and ap x- ray evaluation of the fracture. following general anesthesia, closed reduction of the fracture will be performed. it will be followed by nail insertion, percutaneously, according to standard surgical techniques, with the help of the insertion handle and without preliminary reaming. following insertion the nail will be locked both distally and proximally using interlocking screws. the nail and screws insertion will be monitored by fluoroscopy. patients will remain under follow up for 6 months following the procedure. in the follow up sessions the fracture will be evaluated by fluoroscopy or x-ray for correct bone alignment, callus formation, and fracture union.

Eligibility criteria:
inclusion criteria: * above 18 years old. * mid shaft diaphyseal fracture * acute fracture exclusion criteria: * patients with metabolic or hormonal diseases that could affect bone healing such as diabetes. * ongoing infection in fracture site.
ursodiol for treating parenteral nutrition associated cholestasis in neonates

Conditions: Cholestasis

Summary: the purpose of this study is to determine whether ursodiol is effective in the treatment of parenteral nutrition associated cholestasis in neonates.

this is the first randomised controlled study that address the question of the role of ursodiol as treatment of cases of pnac. it includes all neonates with stratification of less than and equal to 32 weeks or more than 32 weeks of gestation.

Eligibility criteria:
inclusion criteria: * preterm or in-term newborns hospitalized in neonatal care units at chu sainte-justine between october 1st 2008 and october 1st 2011. * must be receiving parenteral nutrition (either partial or total) at the diagnosis of cholestasis. * parental consent must be obtained. exclusion criteria: * active urinary tract infection * presence of clinical signs(acholic stool) of or ultrasound evidence of biliary tract anomalies. * positive torch infections(toxoplasmosis, other infections, rubella, cytomegalovirus, herpes simplex virus) * known short bowel syndrome * known congenital hypothyroidism * known genetic disorders associated with cholestasis like galactosemia, phenylcytonuria, antitrypsin 1 deficiency... etc

Keywords: parenteral nutrition associated cholestasis in neonates parenteral nutrition induced cholestasis in preterms bile duct obstruction biliary stasis
preliminary outcomes of sacral neuromodulation applications; tertiary-center experience in turkey

Conditions: Sacral Neuromodulation

Summary: to report our patients' outcomes of snm in tertiary health centres in turkey

we retrospectively analyzed 18 patients who underwent snm for urinary or bowel dysfunction between 2017 and 2022 in our clinic. we excluded 2 patients due to non-effective responses after the test period. after local ethics committee approval was obtained from our institute (number and date: 21-12.1t/14). patient characteristics and demographic data including age, gender, indications to the snm, age at diagnosis, and comorbidities were collected from our hospital patients' record system. urinary functions were evaluated by the iciq-sf questionnaire form. patients' diagnosis, implantation duration, complications, and improvement of symptoms were recorded.

Eligibility criteria:
inclusion criteria: * patients diagnosed with urinary incontinence * patients diagnosed with faecal incontinence * patients diagnosed with interstitial cystitis exclusion criteria: * presence of urinary infection * presence of previous incontinence surgery * presence of 2nd motor neurone disease * inability of detrusor muscle contraction activity * previous radical cystoprostatectomy history * presence of bladder outlet obstruction

Keywords: sacral neuromodulation overactive bladder urinary incontinence fecal incontinence lower urinary tract dysfunction